KME-3859|CAS 2968466-04-6|DC Chemicals

Cas No.:	2968466-04-6
Chemical Name:	KME-3859
Formula:	C₁₈H₂₁N₅O
M.Wt:	323.4

Cat. No.	Product name	Field of application
DC47009	Zabedosertib	Zabedosertib (BAY 1834845) is a IRAK4 inhibitor with immunomodulatory potential. IRAK4 is a protein kinase involved in signaling innate immune responses from Toll-like receptors.
DC9491	IRAK inhibitor 1	IRAK inhibitor 1 is an interleukin-1 receptor associated kinase 4 (IRAK-4) inhibitor.
DC76682	Emavusertib tosylate	Emavusertib tosylate (CA-4948 tosylate) is the tosylate salt form of Emavusertib. 12-((4-Bromobutyl)amino)dodecanoic acid can be utilized in PROTAC synthesis.
DC76681	Emavusertib phosphate	Emavusertib phosphate (CA-4948 phosphate) is the phosphate salt form of Emavusertib-induced mechanical hyperalgesia in rats. BI-113823 can be used for the research of chronic inflammatory pain.
DC76680	Emavusertib mesylate	Emavusertib mesylate (CA-4948 mesylate) is the mesylate salt form of Emavusertib-stimulated cAMP production with an IC50 value of 18 nM. L-796778 acetate has anticonvulsant effect.
DC76679	Emavusertib maleate	Emavusertib maleate (CA-4948 maleate) is the maleate salt form of Emavusertib that can be extracted from C. forskohlii. Deacetylforskolin activates rat adipocyte adenylyl cyclase (IC50 = 20 µM), inhibits glucose transport in rat adipocyte plasma membranes and exhibits antihypertensive activity.
DC73521	KME-3859	KME-3859 is a potent, selective IRAK4 inhibitor with IC50 of 5 nM, 100-fold selective over IRAK1.
DC73520	KME-2780	KME-2780 (KME2780) is a potent and selective dual IRAK1 and IRAK4 (IRAK1/4) inhibitor with IC50 of 19 and 0.5 nM, respectively.
DC72350	KTX-955	KTX-955 is a potent IRAK4 degrader with DC50 values of 5 nM and 130 nM for IRAK4 and Ikaros, respectively. KTX-955 can be used to research anticancer.
DC72208	KTX-582	KTX-582 is a potent IRAK4 degrader with DC50 values of 4 nM and 5 nM for IRAK4 and Ikaros, respectively. KTX-582 can induce apoptosis in MYD88MT DLBCL, and is efficient to induce in vivo tumor regressions in lymphoma model.